ITGAE and neoplasm: This implies that cancer cells at the leading edge of an invasive tumour that contain activated β-catenin could indirectly resist immune attack.37 The activation of Wnt/β-catenin in tumour cells can also function in immune evasion by inhibiting the recruitment of CD103+ dendritic cells, which are critical for adaptive immune recognition of the tumour.14,129